- Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
- Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
- Reneo Announces Pricing of Public Offering of Common Stock
- Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
More ▼
Key statistics
As of last trade, Reneo Pharmaceuticals Inc (RPHM:NMQ) traded at 1.77, 80.59% above the 52 week low of 0.9801 set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | 1.72 |
Offer | 1.86 |
Previous close | 1.77 |
Average volume | 103.16k |
---|---|
Shares outstanding | 33.42m |
Free float | 32.42m |
P/E (TTM) | -- |
Market cap | 59.15m USD |
EPS (TTM) | -2.52 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 21:00 BST.
More ▼